26 MAY 2021 – BACK TO THE FUTURE: HIV VACCINE LEARNINGS
An event to engage scientists, clinicians, industry, funders, and community representatives on how best to learn from past efficacy trials to inform future vaccine development efforts.
Entries by Roger Tatoud
18 May 2021 – HIV Vaccine Awareness Day
Today, the Journal of the International AIDS Society (JIAS) commemorates HIV Vaccine Awareness Day and reflects on the long-standing efforts to develop an HIV vaccine and the significance of SARS-CoV-2 vaccine development over the past year for the future of HIV vaccine research.
Enterprise – IAVI Communication Training Workshop 2021
The Global HIV Vaccine Enterprise at the IAS – International AIDS Society, and IAVI, are pleased to announce a Communication Training Workshop for early-mid career African researchers working in HIV vaccine research and development.
Enterprise – Communication Training Workshop 2021 (announcement)
The Global HIV Vaccine Enterprise at the IAS – International AIDS Society, and IAVI, are pleased to announce a Communication Training Workshop for early-mid career African researchers working in HIV vaccine research and development.
Enterprise – IAVI Communication Training Workshop 2021
The Global HIV Vaccine Enterprise at the IAS – International AIDS Society, and IAVI, are pleased to announce a Communication Training Workshop for early-mid career African researchers working in HIV vaccine research and development.
How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response
In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.
AMP studies demonstrate proof of concept of passive immunization for HIV prevention
The IAS-led Global HIV Vaccine Enterprise welcomes new results from the AMP proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections.
HIV R4P Virtual News
HIV vaccine highlights and spotlights – To help attendees manage their time and navigate a busy programme, the Enterprise has developed an HIV vaccine R&D roadmap which covers active immunization and passive immunization with broadly neutralizing antibodies (bNAbs), especially VRC01.
VIDEO recording available – Making mAb Accessible webinar
VIDEO – Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’
The video recording of the Global HIV Vaccine Enterprise and IAVI webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention is now available online.
Contact Us
